GLP-1 Medications and Brain Health: What the Alzheimer’s Trials Mean for You
Why thoughtful weight management, metabolic health, and healthy brain aging still belong in the same conversation.
Could a medication used for weight management also help protect memory?
It is an understandable question, especially for someone managing weight or blood-sugar concerns while thinking about their long-term brain health.
Two large clinical trials recently tested whether semaglutide could slow early Alzheimer’s disease. Unfortunately, it did not provide the benefit researchers had hoped for.
That finding matters. But understanding what it means requires separating two different questions: Can a medication treat Alzheimer’s disease once symptoms have developed? And how should we address the health factors that may influence our brains over time?
As a neurologist with additional board certification in obesity medicine and lifestyle medicine, I approach these questions together—but not as though they have the same answer.
What did the Alzheimer’s trials show?
The studies, called EVOKE and EVOKE+, enrolled more than 3,800 adults with mild cognitive impairment or mild dementia caused by Alzheimer’s disease. Participants received either a daily semaglutide pill or a placebo, alongside their usual care.
Over approximately two years, semaglutide did not significantly slow worsening in memory, thinking, or everyday functioning compared with placebo.
Researchers did observe changes in some laboratory markers related to the disease. However, those changes did not translate into better clinical outcomes. A change in a laboratory measurement is not the same as helping someone remember, manage daily activities, or remain independent.
These results do not support using semaglutide to slow early Alzheimer’s disease.
Could taking a GLP-1 medication earlier make a difference?
This remains an important research question—not an established benefit.
Some earlier research found fewer new Alzheimer’s diagnoses among people with type 2 diabetes taking semaglutide compared with people taking other diabetes medications. Those findings helped generate interest in the medication’s potential effects on the brain.
But an association is not proof of prevention. People receiving different medications may also differ in their underlying health, access to care, or other factors that affect their risk.
The Alzheimer’s trials studied people who already had symptoms. They did not establish whether treatment years earlier would reduce the chance of developing dementia. It would therefore be premature to conclude that treatment failed simply because it started “too late.”
We do not yet know whether GLP-1 medications can prevent Alzheimer’s disease.
That uncertainty should guide how we discuss these medications with patients. There is room for continued research, but not for promises that go beyond the evidence.
Why metabolic health still matters for your brain
The connection between metabolic health and brain health does not depend on one medication succeeding in an Alzheimer’s trial.
Blood pressure, blood sugar, cholesterol, physical activity, and other aspects of cardiovascular and metabolic health are relevant to cognitive health. Addressing these factors is part of caring for the whole person—not a separate concern that becomes unimportant when the conversation turns to memory.
Semaglutide also has meaningful benefits that have been demonstrated outside Alzheimer’s disease. In people with overweight or obesity and established cardiovascular disease, including those without diabetes, it has been shown to reduce major cardiovascular events.
That is an important benefit in an appropriate patient population. It is not proof of Alzheimer’s prevention.
The distinction is straightforward: a medication can be valuable for treating one medical condition without being a proven treatment for another.
For an eligible patient, treating obesity or diabetes does not need an additional promise of dementia prevention to be worthwhile.
Good GLP-1 care should go beyond the number on the scale
My obesity medicine training is part of why I view weight management as medical care—not simply a cosmetic goal.
When considering or managing a GLP-1 medication, the question is not only, “How much weight have you lost?” It is also, “Is treatment helping you become healthier, stronger, and better able to function?”
Appetite suppression and weight loss can create challenges as well as benefits. Adequate nutrition, sufficient protein, strength training, hydration, and attention to side effects are important parts of treatment.
In my practice, that means looking at whether the medication and dose remain appropriate, whether you are eating adequately, how treatment affects your daily life, and what your maintenance plan will look like. When useful, body-composition assessment or selected laboratory testing may help answer a specific clinical question.
The goal is not to pursue the lowest possible weight. It is to make treatment serve your health.
That perspective becomes especially important when the broader goal is healthy aging rather than weight loss alone.
Learn how this approach informs my GLP-1 & Neurometabolic Care, including consultations and individualized ongoing management.
What “brain longevity” means in my practice
I use the term brain longevity to describe proactive, individualized care aimed at supporting thinking, memory, physical function, and independence over time.
It is not a promise to prevent dementia, reverse aging, or prescribe a particular medication.
Neurometabolic care brings the relationship between metabolic and neurological health into that plan. Depending on your history and goals, this may involve reviewing blood-sugar regulation, weight-related health risks, nutrition, strength, sleep, medications, and neurological symptoms.
For one patient, a GLP-1 medication may be an appropriate part of care. For another, the priorities may be improving sleep, managing blood pressure, building a sustainable exercise routine, or evaluating a memory concern.
Not everyone needs medication, extensive testing, or the same monitoring tools.
Research supports taking a broader approach. Among older adults at increased risk of cognitive decline, a structured program combining exercise, nutrition, cognitive and social activity, and cardiovascular health monitoring produced modestly greater improvements in cognitive testing than a less intensive, self-guided approach over two years. That does not establish that such a program prevents dementia, but it supports paying attention to several aspects of health together.
For me, the practical lesson is to focus on an individualized plan, consistent support, and follow-through—not to expect a single medication to do everything.
My Brain Longevity & Healthy Aging page explains how I approach proactive neurological health and individualized planning for healthy aging.
Where menopause-informed care fits
For women in midlife, the conversation may also include perimenopause and menopause.
Sleep disruption, mood changes, and difficulties with concentration can overlap during this transition. These symptoms deserve thoughtful assessment rather than being dismissed as “just aging” or automatically assumed to represent a memory disorder.
My menopause background helps me consider these factors alongside neurological and metabolic health.
Treatment should be guided by the individual’s symptoms, medical history, and risks. Hormone therapy may be appropriate for specific menopause-related concerns, but it should not be presented as a proven way to prevent dementia.
The goal is to understand what is affecting how you feel and function today while also considering your longer-term health.
What should you take away from this research?
Already taking a GLP-1 medication? The Alzheimer’s results alone are not a reason to abandon treatment prescribed for another appropriate medical purpose. Review your goals, benefits, side effects, nutrition, and long-term plan with your prescribing clinician. The reasons for continuing treatment should be grounded in your own health needs.
Concerned about memory or brain fog? Do not assume that weight loss or a GLP-1 prescription will address the cause. New or progressive symptoms deserve an appropriate memory and cognitive evaluation. Metabolic and lifestyle care can complement neurological care, but should not replace it.
Thinking proactively about healthy aging? There are worthwhile steps to take without assuming that any medication guarantees protection. Identifying and managing relevant health risks is a reasonable starting point.
Most importantly, a disappointing trial should not leave you feeling that caring for your health is pointless—or that developing memory symptoms means there is nothing left to do.
Looking for a more personalized approach to metabolic and brain health?
Whether you are considering a GLP-1 medication, already receiving treatment, or thinking proactively about healthy brain aging, your care should reflect more than a number on the scale.
At Cardiel Precision Brain Health in Midtown Manhattan, Dr. Myrna Cardiel combines expertise in neurology, obesity medicine, lifestyle medicine, and menopause-informed care to help you understand your options and develop an individualized plan.
Explore GLP-1 & Neurometabolic Care or Brain Longevity & Healthy Aging to learn more.
Request a ConsultationThis article provides general education and does not replace individualized medical advice. Medication decisions should be made with a clinician who knows your medical history.
References
- Cummings JL, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet. 2026. doi: 10.1016/S0140-6736(26)00459-9.
- Wang W, et al. Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer’s & Dementia. 2024;20:8661–8672. doi: 10.1002/alz.14313.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389:2221–2232. doi: 10.1056/NEJMoa2307563.
- American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society. Nutritional priorities to support GLP-1 therapy for obesity. Joint advisory. 2025.
- Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: The US POINTER randomized clinical trial. JAMA. 2025;334(8):681–691. doi: 10.1001/jama.2025.12923.
- National Institute on Aging. Cognitive health and older adults. Patient education resource.
- The Menopause Society. Mental health: Memory and cognition. Patient education resource.
